Skip to main content
Premium Trial:

Request an Annual Quote

Amersham is Granted Favorable Ruling Over PE

Premium

FOSTER CITY, Calif.--Nycomed Amersham last week said its life science unit, Amersham Pharma-cia Biotech, was granted two favorable rulings by a California District Court in its intellectual property action against PE Biosys-tems. The lawsuit relates to use of energy transfer dyes that are used to enable high throughput DNA sequencing. Amersham, which licenses rights to US Patent No. 5,688,648 from the University of California, Berkeley, anticipated that the case would come to trial in January 2001. PE Biosystems contended that Amersham’s claims are invalid because of prior technical work published by others. PE also has a suit against Amersham relating to Amersham’s MegaBACE DNA sequencing instrument.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.